In the BioHarmony Drug Report Database

"Preview" Icon

Ziprasidone

Geodon (ziprasidone) is a small molecule pharmaceutical. Ziprasidone was first approved as Geodon on 2001-02-05. It is used to treat schizophrenia, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, and sodium-dependent noradrenaline transporter.

 

Trade Name

 

Geodon
 

Common Name

 

ziprasidone
 

ChEMBL ID

 

CHEMBL708
 

Indication

 

schizophrenia, schizophrenia spectrum and other psychotic disorders, tourette syndrome
 

Drug Class

 

Antipsychotic with binding activity on serotonin (5HT2A) and dopamine (D2) receptors

Image (chem structure or protein)

Ziprasidone structure rendering